|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC4A10 |
Gene summary for SLC4A10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC4A10 | Gene ID | 57282 |
| Gene name | solute carrier family 4 member 10 | |
| Gene Alias | NBCn2 | |
| Cytomap | 2q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q6U841 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57282 | SLC4A10 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.02e-04 | -2.48e-01 | 0.0155 |
| 57282 | SLC4A10 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.12e-03 | -2.43e-01 | 0.096 |
| 57282 | SLC4A10 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.19e-05 | -2.39e-01 | 0.0674 |
| 57282 | SLC4A10 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.42e-05 | -1.95e-01 | 0.3859 |
| 57282 | SLC4A10 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.71e-06 | -2.35e-01 | 0.3005 |
| 57282 | SLC4A10 | F007 | Human | Colorectum | FAP | 1.73e-04 | -2.75e-01 | 0.1176 |
| 57282 | SLC4A10 | A002-C-010 | Human | Colorectum | FAP | 5.21e-09 | -2.49e-01 | 0.242 |
| 57282 | SLC4A10 | A001-C-207 | Human | Colorectum | FAP | 1.43e-04 | -2.58e-01 | 0.1278 |
| 57282 | SLC4A10 | A015-C-203 | Human | Colorectum | FAP | 1.38e-08 | -2.47e-01 | -0.1294 |
| 57282 | SLC4A10 | A002-C-201 | Human | Colorectum | FAP | 2.16e-04 | -2.19e-01 | 0.0324 |
| 57282 | SLC4A10 | A002-C-203 | Human | Colorectum | FAP | 6.15e-09 | -2.70e-01 | 0.2786 |
| 57282 | SLC4A10 | A001-C-119 | Human | Colorectum | FAP | 3.91e-02 | -2.39e-01 | -0.1557 |
| 57282 | SLC4A10 | A001-C-108 | Human | Colorectum | FAP | 2.63e-08 | -2.54e-01 | -0.0272 |
| 57282 | SLC4A10 | A002-C-205 | Human | Colorectum | FAP | 1.51e-05 | -2.18e-01 | -0.1236 |
| 57282 | SLC4A10 | A001-C-104 | Human | Colorectum | FAP | 5.88e-07 | -2.55e-01 | 0.0184 |
| 57282 | SLC4A10 | A015-C-005 | Human | Colorectum | FAP | 1.64e-03 | -2.35e-01 | -0.0336 |
| 57282 | SLC4A10 | A015-C-006 | Human | Colorectum | FAP | 2.23e-02 | -2.16e-01 | -0.0994 |
| 57282 | SLC4A10 | A015-C-106 | Human | Colorectum | FAP | 2.68e-05 | -2.22e-01 | -0.0511 |
| 57282 | SLC4A10 | A002-C-114 | Human | Colorectum | FAP | 4.54e-03 | -1.91e-01 | -0.1561 |
| 57282 | SLC4A10 | A015-C-104 | Human | Colorectum | FAP | 7.82e-13 | -2.75e-01 | -0.1899 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1902600 | Colorectum | AD | proton transmembrane transport | 66/3918 | 157/18723 | 1.59e-09 | 1.17e-07 | 66 |
| GO:0021859 | Colorectum | AD | pyramidal neuron differentiation | 9/3918 | 13/18723 | 2.38e-04 | 3.03e-03 | 9 |
| GO:0021860 | Colorectum | AD | pyramidal neuron development | 8/3918 | 11/18723 | 3.26e-04 | 3.85e-03 | 8 |
| GO:0030004 | Colorectum | AD | cellular monovalent inorganic cation homeostasis | 36/3918 | 103/18723 | 6.80e-04 | 6.95e-03 | 36 |
| GO:0009791 | Colorectum | AD | post-embryonic development | 29/3918 | 80/18723 | 1.13e-03 | 1.03e-02 | 29 |
| GO:0030641 | Colorectum | AD | regulation of cellular pH | 29/3918 | 81/18723 | 1.42e-03 | 1.22e-02 | 29 |
| GO:0051453 | Colorectum | AD | regulation of intracellular pH | 26/3918 | 75/18723 | 4.04e-03 | 2.82e-02 | 26 |
| GO:0006885 | Colorectum | AD | regulation of pH | 30/3918 | 91/18723 | 4.95e-03 | 3.32e-02 | 30 |
| GO:0055067 | Colorectum | AD | monovalent inorganic cation homeostasis | 45/3918 | 151/18723 | 6.19e-03 | 3.88e-02 | 45 |
| GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
| GO:19026002 | Colorectum | MSS | proton transmembrane transport | 57/3467 | 157/18723 | 1.00e-07 | 4.81e-06 | 57 |
| GO:00097912 | Colorectum | MSS | post-embryonic development | 26/3467 | 80/18723 | 1.91e-03 | 1.66e-02 | 26 |
| GO:00300042 | Colorectum | MSS | cellular monovalent inorganic cation homeostasis | 31/3467 | 103/18723 | 2.94e-03 | 2.27e-02 | 31 |
| GO:0035264 | Colorectum | MSS | multicellular organism growth | 37/3467 | 132/18723 | 4.77e-03 | 3.34e-02 | 37 |
| GO:00306412 | Colorectum | MSS | regulation of cellular pH | 25/3467 | 81/18723 | 4.97e-03 | 3.46e-02 | 25 |
| GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
| GO:19026004 | Colorectum | FAP | proton transmembrane transport | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
| GO:00300043 | Colorectum | FAP | cellular monovalent inorganic cation homeostasis | 28/2622 | 103/18723 | 3.23e-04 | 4.15e-03 | 28 |
| GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
| GO:00514532 | Colorectum | FAP | regulation of intracellular pH | 22/2622 | 75/18723 | 4.38e-04 | 5.21e-03 | 22 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC4A10 | SNV | Missense_Mutation | rs267598941 | c.1390G>A | p.Glu464Lys | p.E464K | Q6U841 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| SLC4A10 | SNV | Missense_Mutation | c.2806N>T | p.Pro936Ser | p.P936S | Q6U841 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SLC4A10 | SNV | Missense_Mutation | novel | c.421N>G | p.Leu141Val | p.L141V | Q6U841 | protein_coding | tolerated(0.42) | benign(0.251) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR |
| SLC4A10 | SNV | Missense_Mutation | novel | c.1525N>C | p.Cys509Arg | p.C509R | Q6U841 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC4A10 | SNV | Missense_Mutation | novel | c.1908N>A | p.Phe636Leu | p.F636L | Q6U841 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC4A10 | insertion | Frame_Shift_Ins | novel | c.2344_2345insATGTTATGAGTATATA | p.Pro782HisfsTer20 | p.P782Hfs*20 | Q6U841 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SLC4A10 | SNV | Missense_Mutation | novel | c.1481C>T | p.Ala494Val | p.A494V | Q6U841 | protein_coding | tolerated(0.37) | benign(0.375) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC4A10 | SNV | Missense_Mutation | c.1398G>C | p.Glu466Asp | p.E466D | Q6U841 | protein_coding | tolerated(0.12) | benign(0.065) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC4A10 | SNV | Missense_Mutation | novel | c.2221N>A | p.Ala741Thr | p.A741T | Q6U841 | protein_coding | tolerated(0.45) | benign(0.01) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| SLC4A10 | SNV | Missense_Mutation | c.218N>A | p.Arg73Lys | p.R73K | Q6U841 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |